In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.

You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.

19-01-2016

Kedrion Biopharma strengthens its position on the US market

Kedrion Biopharma will commercialize a 10% concentrated intravenous liquid immunoglobulin (IVIg) on the US market, indicated for the treatment of Primary Immunodeficiencies (PI), on an exclusive basis. The product will enable the company, based in Castelvecchio Pascoli (Lucca), Italy’s leader and the 5th most important manufacturer of plasma-derived products in the world, to strengthen its immunoglobulin portfolio in the US.

The result is a seven year agreement signed with the US company Biotest Pharmaceuticals Corporation, a subsidiary of Biotest AG, Dreieich, Germany.

Kedrion Biopharma started its activities in the United States of America eleven years ago, opening three plasma-collection centers (now twelve). Over the years, the company’s US operations have also been boosted by a number of major investments, primarily the acquisition of a manufacturing plant in Melville, State of New York, in 2011, and the later acquisition of a division specializing in the manufacturing and marketing of a hyperimmune globulin used in the clinical practice for over half a century in the treatment of the Hemolytic Disease of the Fetus and the Newborn (HDFN).

The present agreement will enable Kedrion Biopharma to further increase the turnover generated by its operations in the US, which are currently the Lucca-based company’s main market (accounting, in 2014, for 160 Million Euros of company’s overall turnover of 466 Million Euros). In addition to which, this deal will have implications on Kedrion Biopharma’s activities in Italy too, as it has already been decided that, in the future, a phase of the manufacturing process (filling) will be carried out at the company’s facility in Bolognana, Lucca.

“Under this agreement – commented Paolo Marcucci, Kedrion Biopharma President and CEO – we will have the chance not only to grow further on what is considered the most important market in the world; we will also be able to stand out as a market leader in plasma-derived therapies for the treatment of rare diseases. An area in which Kedrion Biopharma has been working hard since its foundation and with growing commitment, in partnership with patients’ associations, with the ultimate goal of broadening as much as possible the access to care for all those who need it.”